See Important Safety Information below for combined NOVA and QUADRA safety profile
NOVA: Non-hematologic ARs
The Side Effect Profile of ZEJULA Is Well-Characterized1
Adverse reactions (ARs) reported in ≥10% of patients receiving ZEJULA1
CTCAE, Common Terminology Criteria for Adverse Events, version 4.02.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Side effects were manageable with dose interruption and modification.
- ARs led to dose reduction or interruption in 69% of patients, most frequently from thrombocytopenia (41%) and anemia (20%)1,2
- No increase in all-grade diarrhea was observed with ZEJULA vs placebo1
- No on-treatment deaths were reported during the study2
References: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: TESARO, Inc.; October 2019. 2. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164, and Supplementary Appendix.